Multidisciplinary management of non small cell lung cancer (NSCLC) in stage III: clinical case description. Recommendations and state of the art
DOI:
https://doi.org/10.7175/cmi.v7i1.632Keywords:
Non small cell lung cancer, Multidisciplinary management, Stage III disease, TherapyAbstract
Lung cancer is the leading cause of cancer death in industrialized countries with progressive increase of its mortality rate. Non Small Cell Lung Cancer (NSCLC ) is approximately 80-85% of all lung cancers, being adenocarcinoma and squamous cell carcinoma the most common histologies. The majority of the patients with stage III clinical stage, presents a mediastinal lymph node involvement described with computed tomography (TC) and/or positron emission tomography (PET). The current approach to patients with NSCLC is multidisciplinary, especially for those staged as potentially operable, both for staging and for a correct definition of best treatment strategy. Updated international and national Guidelines and recommendations can provide valuable support to the clinician.
The case described concerns the accidental detection of a tumour in the lung in a 58-year-old man with arterial hypertension controlled with ACE inhibitors. The treatments agreed after a multidisciplinary approach are cisplatin and docetaxel, the surgical resection, and the radiotherapy. After three months the patient has neither metastasis nor relapse.
References
Jemal A, Bray F, Center MM ,et al “ Global cancer statistics ”. CA Cancer J Clin 2011; 61:69-90
Ferlay J, Parkin DM, Steliarova-Foucher E, “Estimates of cancer incidence and mortality in Europe in 2008”. Eur J Cancer. 2010 Mar;46(4):765-81
Malvezzi M, Bertuccio P, Levi F et al, “ European cancer mortality predictions for year 2012”. Ann. Oncol 2012; 23: 1044-1052”
Dati del Reparto di Epidemiologia dei Tumori del Centro Nazionale di Epidemiologia Sorveglianza e Promozione della Salute dell’Istituto Superiore di Sanità
Mountain CF, Dresler CM, “ Regional Lymph node classification for lung cancer staging ”. Chest 1997; 11:1718-1723
Rusch VW, Asamura H, Watanabe H and Members of IASLC Staging Committee, “The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer ”, J Thorac Oncol. 2009 May;4(5):568-77.
Goldstraw P, Crowley J, Chansky K, et al “The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours ”, J Thorac Oncol. 2007 Aug;2(8):706-14
Eisenhauer E.A, Therasse P, Bogaerts J, et al “New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)”,European Journal of Cancer, 2009; 228-247
Burt ME, Pomerantz AH, Bains MS, et al “ Results of surgical treatment of stage III lung cancer invading the mediastinum ”. Surg Clin North Am 1987; 67:987-1000
Scagliotti GV, Pastorino U, Vansteenkiste JF, et al “ Preliminary results of C.H.E.S.T: a phase III randomized study of surgery alone or surgery plus pre-operative gemcitabine-cisplatin in early stages NSCLC. Follow-up data of CHEST trial ”, J Clin Oncol 2008; 25:399s
Douillard JY, Rosell R, De Lena M, et al “ Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non small cell lung cancer ( Adjuvant Navelbine International Trialist Association [ ANITA ] ): a randomized controlled trial ”, Lancet Oncol 2006;7:719-727
Scagliotti GV, Fossati R, Torri V, et al “ Randomized study of adjuvant chemotherapy for completely resected stage I, II o IIIA non small cell lung cancer ”. J Natl Cancer Inst 2003; 95:1453-1461
Burdett S, Stewart LA, Rydzewska L “ A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non small cell lung cancer ”, J Thorac Oncol 2006; 1:611-621
Albain KS, Swann RS, Rusch VW, et al “ Radiotherapy plus chemotherapy with or without surgical resection for stage III non small cell lung cancer : a phase III randomized controlled trial ”, Lancet 2009; 374:379-386
AIOM, Linee Guida neoplasie del polmone, 2012, pag:28-30; Disponibile all’indirizzo: http:// www.aiom.it
Huber RM et al, “Simultaneous chemoradiotherapy compared with radiotherapy aloneafter induction chemotherapy in inoperabile Stage IIIA or IIIB NSCLC ”, J Clin Oncol 2006;24:4397-4404
Mc Caughan BC, et al “ Primary lung cancer invading the chest wall ”, Chest Surg Clin North Am. 1994; 4:17-28
AIOM, Linee Guida neoplasie del polmone, 2012, pag:15; Disponibile all’indirizzo: http:// www.aiom.it
Silvestri GA, Gould MK, Margolis ML et al “ Noninvasive staging of non small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition) ”, Chest 2007; 132:178S-201S
Detterbeck FC, Jantz MA, Wallance M, et al “ Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines ( 2nd edition ) ”, Chest 2007; 132: 202S-220S
Kiser AC, Detterbeck FC “ General aspects of surgical treatment ” In: Detterbeck FC. Rivera MP. Socinski MA, et al, eds “ Diagnosis and treatment of lung cancer: an evidence based guide for the practicing clinician ”. Philadelphia, PA: WB Saunders, 2001¸pg. 133-147
Gilligan D, Nicolson M, Smith I,et al “Preoperative chemotherapy in patients with resectable non small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomized trial and update of systematic review ”, Lancet 2007;369:1929-1937
Poldermans D, Jeroen J. Bax, Boersma E, “Linee Guida per la valutazione preoperatoria del rischio cardiaco e la gestione perioperatoria del paziente cardiopatico nella chirurgia non cardiaca ”, G Ital Cardiol 2010; 11 (10 Suppl 2): e136-e181
Valutazione preoperatoria del paziente da sottoporre a chirurgia elettiva, Linee guida nazionali di riferimento, Luglio 2005
Azzolina R, Cantarella G, La Camera G, “The spirometric examination how mean diagnostic pre-operating for appraising the functional respiratory reserves, the possibilities of remuneration and the anesthesiological risk in the patients with severe BPCO”, Acta Medica Mediterranea, 2010, 26: 67
Celli BR, Cote CG, Marin JM, et al “The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease ”, N Engl J Med. 2004; 350:1005-12
Boffa DJ, Allen MS, Grab JD, et al “ Data from the Society of Thoracic Surgeons, General Thoracic Surgery Database: The surgical management of primary lung tumors ”, J Thorac Cardiovas Surg 2008 Feb;135:247-54
Perrot E, Guibert B, Mulsant P, et al “ Preoperative chemotherapy does not increase complications after non small cell lung cancer resection ”, Ann Thorac Surg 2005; 80:423-427
Brunelli A, Xiumé F. Refai MA, et al “ Gemcitabine-cisplatin chemotherapy before lun resention: a case-matched analysis of early outcome ” Ann Thorac Surg 2006; 81:1963-1968
Venuta F, Anile M, Diso D, et al “ Operative complications and early mortality after induction therapy for lung cancer ”, Eur J Cardiothorac Surg 2007;31: 714-718
Felip E, Rosell R, Maestre JA, et al “ Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non small cell lung cancer ”, J Clin Oncol 2010; 28:3138-3145
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), “ Non Small Cell Lung Cancer ”version 3.2012; Disponibile all’indirizzo: http:// www.nccn.com
AIOM,” Linee Guida Neoplasia Polmone 2012”; Disponibile all’indirizzo: http:// www.aiom.it
Doddoli C, Barlesi F, Trousse D, et al “ One hundred consecutive pneumonectomies after induction therapy for non small cell lung cancer: an uncertain balance between risks and benefits ”, Thorac Cardiovasc Surg 2005; 130:416-425t
Cho GH, Kim J, Kim K, et al “ Risk associated with bilobectomy after neoadjuvant concurrent chemoradiotherapy for stage IIIA-N2 non-small-cell lung cancer”, World J Surg. 2012 May;36(5):1199-205
Pisters KMW, Evans WK, Azzoli CG, et al “Cancer care Ontario and American Society of clinical oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small cell lung cancer guideline ”, J Clin Oncol 2007;25:5506-5518
Crinò L,Weder W,van Meerbeeck J, et al “ Early stage and locally advanced (non metastatic) non small cell lung cancer: ESMO Clinical Practise Guidelines for diagnosis, treatment and follow-up ”, Ann Oncol 2010;21(Suppl 5):v103-v115
AIOM, Linee Guida neoplasie del polmone, 2012, 25-32; Disponibile all’indirizzo: http:// www.aiom.it
Gandara DR, Chansky K, “ Long term survival with concurrent chemoradiation therapy followed by consolidan docetaxel in stage IIIB NSCLC: a phase II Southwest Oncology Group Study ( S9504 )”, Clin Lung cancer 2006; 08:116-121
AIOM, Linee Guida neoplasie del polmone, 2012, 32-33; Disponibile all’indirizzo: http:// www.aiom.it
Albain KS, Crowley JJ, Turrisi AT 3rd, “ Concurrent cisplatin, etoposide anch chest radiotherapy in pathologic stage IIIB NSCLC: a southwest Oncology Group phase II study, SWOG 9019 ”, J Clin Oncol 2002; 20:3454-3460
Socinski MA, Stinchcombe TE, Moore DT, et al “ Incorporating Bevacizumab and Erlotinib in the Combined-Modality Treatment of Stage III Non-Small-Cell Lung Cancer: Results of a Phase I/II Trial ”, J Clin Oncol. 2012 Nov 10;30(32):3953-9
Hallqvist A, Bergman B, Nyman J, “ Health related quality of life in locally advanced NSCLC treated with high dose radiotherapy and concurrent chemotherapy or cetuximab--pooled results from two prospective clinical trials ”. Radiother Oncol. 2012 Jul;104(1):39-44.
Vokes EE, Senan S, Treat JA, et al “ PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology ”, Clin Lung Cancer.2009 May;10(3):193-8
Gandara DR, Chansky K. Long term survival with concurrent chemo-radiation therapy followed by consolidan docetaxel in stage IIIB NSCLC: a phase II Southwest Oncology Group Study (S9504). Clin Lung Cancer 2006; 08: 116-21
Albain KS, Crowley JJ, Turrisi AT 3rd. Concurrent cisplatin, etoposide anch chest radiotherapy in pathologic stage IIIB NSCLC: a southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 2002; 20: 3454-60
Socinski MA, Stinchcombe TE, Moore DT, et al. Incorporating bevacizumab and erlotinib in
the combined-modality treatment of stage III Non-Small-Cell Lung Cancer: results of a phase
I/II trial. J Clin Oncol 2012; 30: 3953-9
Hallqvist A, Bergman B, Nyman J. Health related quality of life in locally advanced NSCLC
treated with high dose radiotherapy and concurrent chemotherapy or cetuximab--pooled results
from two prospective clinical trials. Radiother Oncol 2012; 104: 39-44
Vokes EE, Senan S, Treat JA, et al. PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology. Clin Lung Cancer 2009; 10: 193-8
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non-Commercial 4.0 Licence that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)